Inmune Bio, Inc. Annual Operating Income (Loss) in USD from 2017 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Inmune Bio, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2017 to 2023.
  • Inmune Bio, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$12.3M, a 44.1% decline year-over-year.
  • Inmune Bio, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$41.5M, a 53.9% decline year-over-year.
  • Inmune Bio, Inc. annual Operating Income (Loss) for 2023 was -$29.7M, a 14.6% decline from 2022.
  • Inmune Bio, Inc. annual Operating Income (Loss) for 2022 was -$26M, a 11% increase from 2021.
  • Inmune Bio, Inc. annual Operating Income (Loss) for 2021 was -$29.2M, a 138% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$29.7M -$3.79M -14.6% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-28
2022 -$26M +$3.2M +11% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 -$29.2M -$16.9M -138% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-02
2020 -$12.2M -$4.47M -57.7% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-03
2019 -$7.76M +$4.68M +37.7% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-04
2018 -$12.4M -$11.5M -1167% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-11
2017 -$981K Jan 1, 2017 Dec 31, 2017 10-K 2019-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.